1854943-32-0 Iruplinalkib

Properties

Appearance Off-white to light yellow Solid
Boiling point:769.1±70.0 °C
Density 1.30±0.1 g/cm3
pka10.12±0.20
 

Application:

     Iruplinalkib (WX-0593), also known as Irulak, is a novel ALK/ROS1 tyrosine kinase inhibitor (TKI) developed by Qilu Pharmaceutical. This drug is mainly used to treat advanced non-small cell lung cancer (NSCLC), especially for ALK positive patients.

 

Synonyms:

Iruplinalkib

1854943-32-0

Qixinke

WX-0593

2,4-Pyrimidinediamine, 5-chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(9-methyl-3,9-diazaspiro(5.5)undec-3-yl)phenyl)-

5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-[2-methoxy-4-(9-methyl-3,9-diazaspiro[5.5]undecan-3-yl)phenyl]pyrimidine-2,4-diamine

5-Chloro-N4-(2-(dimethylphosphinyl)phenyl)-N2-(2-methoxy-4-(9-methyl-3,9-diazaspiro(5.5)undec-3-yl)phenyl)-2,4-pyrimidinediamin

5-chloro-4-N-(2-dimethylphosphorylphenyl)-2-N-(2-methoxy-4-(9-methyl-3,9-diazaspiro(5.5)undecan-3-yl)phenyl)pyrimidine-2,4-diamine

ALK Inhibitor WX-0593

GTPL11877

FL006

 

Hot Tags: 1854943-32-0 iruplinalkib, China 1854943-32-0 iruplinalkib manufacturers, suppliers, 1-Benzyl-3-piperidinol, N-Acetyl-D-mannosamine, Hydroxyapatite, 3-Cyanophenylhydrazine, Pcbma, 4-Aminoantipyrine